China SXT Pharmaceuticals, Inc. (SXTC) Financial Ratios
10 years of historical data (2016–2025) · Healthcare · Drug Manufacturers - Specialty & Generic
EV/EBITDA
N/A
—
5yr avg: N/A
30Y Low22.4·High22.4
P/FCF
N/A
—
5yr avg: 212.20
30Y Low196.9·High196.9
P/B Ratio
↓
0.04
↓-100% vs avg
5yr avg: 11.99
30Y Low2.7·High94.7
ROE
↓
-22.5%
↓+19% vs avg
5yr avg: -27.9%
30Y Low-100%·High91%
Debt/EBITDA
N/A
—
5yr avg: N/A
30Y Low0.1·High1.6
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
SXTC Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
China SXT Pharmaceuticals, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $670507 | $151M | $219M | $284M | $44M | $199M | $104M | $1.1B | — | — | — |
| Enterprise Value | $-16444635 | $134M | $209M | $271M | $30M | $185M | $103M | $1.0B | — | — | — |
| P/E Ratio → | -0.20 | — | — | — | — | — | — | 683.50 | — | — | — |
| P/S Ratio | 0.39 | 86.83 | 113.35 | 144.21 | 16.78 | 41.57 | 20.12 | 150.04 | — | — | — |
| P/B Ratio | 0.04 | 9.79 | 15.69 | 19.35 | 2.66 | 12.44 | 11.05 | 94.71 | — | — | — |
| P/FCF | — | — | — | — | 212.20 | — | 196.85 | — | — | — | — |
| P/OCF | — | — | — | — | 162.77 | — | 111.17 | 4398.36 | — | — | — |
P/E links to full P/E history page with 30-year chart
SXTC EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 77.00 | 108.46 | 137.30 | 11.60 | 38.79 | 20.01 | 148.77 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | 22.37 | 534.85 | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | 580.63 | — | — | — |
| EV / FCF | — | — | — | — | 146.71 | — | 195.79 | — | — | — | — |
SXTC Profitability
Margins and return-on-capital ratios measuring operating efficiency
China SXT Pharmaceuticals, Inc. earns an operating margin of -154.0%. Operating margins have expanded from -284.4% to -154.0% over the past 3 years, signaling improving operational efficiency. A negative ROE of -22.5% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 21.1% | 21.1% | 28.7% | 21.6% | 48.1% | 59.4% | 52.4% | 65.8% | 48.5% | 47.4% | 21.4% |
| Operating Margin | -154.0% | -154.0% | -130.4% | -284.4% | -199.4% | -46.0% | 83.0% | 25.2% | 23.3% | 32.8% | 5.6% |
| Net Profit Margin | -189.8% | -189.8% | -160.7% | -301.0% | -220.4% | -57.5% | -199.3% | 22.0% | 16.9% | 24.3% | 3.8% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -22.5% | -22.5% | -21.7% | -38.1% | -35.4% | -21.7% | -100.3% | 21.4% | 46.2% | 91.3% | 19.1% |
| ROA | -14.8% | -14.8% | -11.8% | -18.8% | -16.8% | -9.8% | -52.5% | 12.3% | 18.1% | 20.2% | 2.2% |
| ROIC | -142.0% | -142.0% | -67.5% | -208.9% | -138.6% | -28.6% | 58.0% | 49.6% | 47.1% | 72.8% | 13.0% |
| ROCE | -17.9% | -17.9% | -17.2% | -35.6% | -32.0% | -17.3% | 41.6% | 24.5% | 63.5% | 123.5% | 28.2% |
SXTC Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $18M exceeds total debt of $983877, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.06 | 0.06 | 0.19 | 0.26 | 0.12 | 0.00 | 0.72 | 0.02 | 0.12 | 0.16 | 0.65 |
| Debt / EBITDA | — | — | — | — | — | — | 1.46 | 0.13 | 0.22 | 0.18 | 1.61 |
| Net Debt / Equity | — | -1.11 | -0.68 | -0.93 | -0.82 | -0.83 | -0.06 | -0.80 | -0.05 | 0.13 | 0.63 |
| Net Debt / EBITDA | — | — | — | — | — | — | -0.12 | -4.55 | -0.10 | 0.14 | 1.57 |
| Debt / FCF | — | — | — | — | -65.49 | — | -1.07 | — | -0.20 | 2.22 | 5.47 |
| Interest Coverage | -4.14 | -4.14 | -4.62 | -11.76 | -141.43 | -1.36 | 1.28 | 342.00 | 2095.34 | 39.67 | — |
Net cash position: cash ($18M) exceeds total debt ($983877)
SXTC Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
China SXT Pharmaceuticals, Inc.'s current ratio of 3.54x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 1.35x to 3.54x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.54 | 3.54 | 1.60 | 1.35 | 1.31 | 1.25 | 1.60 | 2.47 | 1.40 | 1.37 | 1.05 |
| Quick Ratio | 3.40 | 3.40 | 1.51 | 1.31 | 1.25 | 1.20 | 1.53 | 2.31 | 1.11 | 1.09 | 0.74 |
| Cash Ratio | 3.01 | 3.01 | 1.36 | 1.20 | 0.91 | 0.72 | 0.59 | 1.44 | 0.13 | 0.02 | 0.00 |
| Asset Turnover | — | 0.08 | 0.08 | 0.07 | 0.08 | 0.14 | 0.24 | 0.40 | 0.92 | 0.90 | 0.59 |
| Inventory Turnover | 1.66 | 1.66 | 1.70 | 2.91 | 1.33 | 2.25 | 2.75 | 2.38 | 2.86 | 2.52 | 1.70 |
| Days Sales Outstanding | — | 398.39 | 254.83 | 248.91 | 775.01 | 593.38 | 752.83 | 256.75 | 203.48 | 239.72 | 398.90 |
SXTC Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
China SXT Pharmaceuticals, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | 0.1% | — | — | — |
| FCF Yield | — | — | — | — | 0.5% | — | 0.5% | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $403920 | $867422 | $266973 | $41591 | $28782 | $12364 | $10284 | $0 | $0 | $0 |
Peer Comparison
Compare SXTC with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 SXTCYou | $670507 | -0.2 | — | — | 21.1% | -154.0% | -22.5% | -142.0% | — |
 SBFM | $757819 | -0.1 | — | — | 30.6% | -16.7% | -23.0% | -42.9% | — |
 CHNR | $42M | -88.6 | — | — | — | — | -0.0% | -0.0% | — |
 TCMD | $587M | 31.7 | 14.5 | 14.5 | 75.2% | 8.9% | 8.8% | 13.8% | 0.4 |
 CODA | $134M | 32.2 | 17.9 | 22.2 | 66.5% | 17.1% | 7.4% | 11.2% | 0.1 |
 CCRN | $423M | -4.5 | 23.7 | 10.6 | 18.7% | -0.3% | -25.6% | -0.9% | 0.2 |
 NVO | $203B | 12.7 | 9.4 | 44.7 | 81.0% | 41.3% | 60.7% | 36.2% | 0.9 |
 PFE | $151B | 19.5 | 10.7 | 16.6 | 70.3% | 24.7% | 8.9% | 7.5% | 3.3 |
 MRK | $277B | 15.4 | 10.7 | 22.4 | 72.0% | 36.2% | 36.9% | 22.0% | 1.7 |
 AMGN | $178B | 23.1 | 14.1 | 21.9 | 70.8% | 29.1% | 106.1% | 14.8% | 3.4 |
 ABBV | $358B | 85.5 | 15.0 | 20.1 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 10 years · Updated daily
See SXTC's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SXTC Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SXTC vs SBFM
Side-by-side business, growth, and profitability comparison vs Sunshine Biopharma, Inc..
Start ComparisonSXTC — Frequently Asked Questions
Quick answers to the most common questions about buying SXTC stock.
What is China SXT Pharmaceuticals, Inc.'s P/E ratio?
China SXT Pharmaceuticals, Inc.'s current P/E ratio is -0.2x. This places it at the 50th percentile of its historical range.
What is China SXT Pharmaceuticals, Inc.'s ROE?
China SXT Pharmaceuticals, Inc.'s return on equity (ROE) is -22.5%. The historical average is -6.2%.
Is SXTC stock overvalued?
Based on historical data, China SXT Pharmaceuticals, Inc. is trading at a P/E of -0.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are China SXT Pharmaceuticals, Inc.'s profit margins?
China SXT Pharmaceuticals, Inc. has 21.1% gross margin and -154.0% operating margin.